PWPS
ZNTL icon

Pinnacle Wealth Planning Services’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-600
Closed -$31K – 2010
2020
Q4 		$31K Buy
+600
New +$27.1K 0.01% 995

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pinnacle Wealth Planning Services's ZNTL Position: Q1 2021 in Review

Pinnacle Wealth Planning Services sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2021, closing a stake of 600 shares — an estimated $31K sold.

Pinnacle Wealth Planning Services first reported a position in ZNTL in Q4 2020 and held it in 1 quarter. The position peaked at $31K in Q4 2020. 95 funds tracked by Wall St. Rank hold ZNTL as of Q1 2021.

  • Pinnacle Wealth Planning Services reported no remaining Zentalis Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Pinnacle Wealth Planning Services sold 600 Zentalis Pharmaceuticals shares in Q1 2021, an estimated $31K.
  • Pinnacle Wealth Planning Services first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Pinnacle Wealth Planning Services's Zentalis Pharmaceuticals position peaked at $31K in Q4 2020.
  • 95 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2021.

Based on Pinnacle Wealth Planning Services's 13F filing for Q1 2021, filed 29 Apr 2021.